What is the purpose of this trial?
This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers.
Ages: 18 - 65 years
Yale University School of Medicine
Dates: 03/16/2016 - 03/15/2018
Last Updated: 03/24/2017
Study HIC#: 1412015121